Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 1, 2022

Rhea-AI Summary

Organogenesis Holdings (Nasdaq: ORGO) will announce its fourth quarter and fiscal year 2021 financial results on March 1, 2022, after market close. Management will discuss these results in a conference call at 5:00 p.m. ET, which is open to participants via a dedicated phone line or a live webcast on the investor relations section of their website. A replay will be available for two weeks post-call. Organogenesis specializes in regenerative medicine, focusing on solutions for advanced wound care and surgical and sports medicine.

Positive

• Forthcoming financial results may show growth potential in regenerative medicine market.
• Company plans a live conference call to engage with investors, promoting transparency.

Negative

• None.

CANTON, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2021 financial results will be reported after the market closes on Tuesday, March 1st.

Management will host a conference call at 5:00 p.m. Eastern Time on March 1st to discuss the results of the quarter and fiscal year, and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 5998131. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com.

For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 5998131. The webcast will be archived at investors.organogenesis.com.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

FAQ

When will Organogenesis announce its fourth quarter and fiscal year 2021 results?

Organogenesis will announce the results on March 1, 2022, after market close.

What time is the Organogenesis conference call?

The conference call is scheduled for 5:00 p.m. ET on March 1, 2022.

How can I participate in the Organogenesis conference call?

Participants can join by calling 866-795-3142 or accessing the live webcast on the company's investor relations website.

Will there be a replay of the Organogenesis conference call?

Yes, a replay will be available for two weeks at 855-859-2056.

What does Organogenesis specialize in?

Organogenesis specializes in regenerative medicine, focusing on advanced wound care and surgical biologics.